What is the current stock price of Central Securities Corp. (CET)?

As of the latest market data, Central Securities Corp. (CET) is trading at $51.56. The stock has seen a gain of 0.12% today.

Does Central Securities Corp. (CET) pay a dividend?

Based on current data, Central Securities Corp. does not have a confirmed active dividend policy.

What is the market cap of Central Securities Corp.?

The current market capitalization of Central Securities Corp. (CET) is approximately unavailable.

Central Securities Corp. (CET) Stock Price, News & Key Metrics

globenewswire.com

Mar 31

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium; March 31, 2026, 7.30 CET; regulated information – Announcement in application of Article 7:97, §4/1 of the BCCA — Galapagos NV (Euronext & NASDAQ: GLPG) (“Galapagos” or the “Company”) today announced that it has entered into a binding agreement (the "Framework Agreement") with Gilead Sciences, Inc. ("Gilead") in connection with Gilead's definitive agreement to acquire all of the outstanding equity interests of US-based Ouro Medicines, LLC ("Ouro"), a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. Gamgertamig (OM336) is a clinical‑stage BCMAxCD3 T cell engager designed to enable rapid and deep plasma and B‑cell depletion following a short duration, subcutaneously administered treatment course.

CET

Coface SA: Combined Shareholders' Meeting on Tuesday, May 19, 2026 at 2:00 p.m. CET

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings

Invitation to Alfa Laval's first quarter conference call

Correction of the publication from 20. Mar 2026/ 09:15 CET/CEST - Deutsche Lufthansa AG: Mr Carsten Spohr, Acquisition

Norsk Hydro: Potential impact on Qatalum aluminium production